- Associated Press - Thursday, October 9, 2014

DALLAS (AP) - Officials of the Dallas hospital that treated the first person to develop Ebola in the United States say he received an experimental drug as soon as doctors deemed it warranted and as soon as it could be obtained.

In a statement Thursday, officials at Texas Health Presbyterian Hospital Dallas recapped Thomas Eric Duncan’s treatment during his weeklong hospitalization before his death Wednesday.

The statement says Duncan received the experimental antiviral drug brincidofovir (brihn-sih-DAH’-fuh-veer) as soon as his condition warranted, becoming the first Ebola patient to receive it.

None of the experimental drug ZMapp given two American medical missionaries stricken in Liberia was available, and serum transfusions from Ebola survivors weren’t given because Duncan’s blood type wasn’t compatible.

Also, Duncan had asked that he not be resuscitated if his heart stopped.

Copyright © 2019 The Washington Times, LLC.

The Washington Times Comment Policy

The Washington Times welcomes your comments on Spot.im, our third-party provider. Please read our Comment Policy before commenting.


Click to Read More and View Comments

Click to Hide